YUNGJIN PHARM has signed Supply Agreement with API CORPORATION(APIC), Japan for supplying of non-steroidal anti-inflammatory drug, Loxoprofen sodium hydrate(API) on July 31, 2018. 

According to the agreement, YUNGJIN PHARM will produce and supply exclusively about 14.8 billion won (Korean currency) of Loxoprofen sodium hydrate, a non-steroidal anti-inflammatory drug to APIC. While APIC will be in charge of purchasing, importing, selling, and marketing for Japan market by 2022.

The raw material of non-steroidal anti-inflammatory drug, Loxoprofen sodium hydrate, inhibits cyclooxygenase which synthesizes prostaglandins and effects on analgesic, antipyretic, and anti-inflammatory.

Although, YUNGJIN PHARM exports mainly Cephalosporins antibiotics to Japan, but this agreement has been recognized for its quality and productivity even for in general products in Japan. Thus, YUNGJIN PHARM has established a bridgehead to expand exporting products from not only Cephalosporins antibiotics, but also to the other general APIs.